These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22841674)

  • 41. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
    J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population.
    Złowocka-Perłowska E; Tołoczko-Grabarek A; Lubiński J
    Hered Cancer Clin Pract; 2022 Jan; 20(1):1. PubMed ID: 34983599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank.
    Wei J; Shi Z; Na R; Wang CH; Resurreccion WK; Zheng SL; Hulick PJ; Cooney KA; Helfand BT; Isaacs WB; Xu J
    Br J Cancer; 2020 Oct; 123(9):1356-1359. PubMed ID: 32830201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate cancer risk variants of the HOXB genetic locus.
    Dupont WD; Breyer JP; Johnson SH; Plummer WD; Smith JR
    Sci Rep; 2021 May; 11(1):11385. PubMed ID: 34059701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
    Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
    Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Germline ATBF1 mutations and prostate cancer risk.
    Xu J; Sauvageot J; Ewing CM; Sun J; Liu W; Isaacs SD; Wiley KE; Diaz L; Zheng SL; Walsh PC; Isaacs WB
    Prostate; 2006 Jul; 66(10):1082-5. PubMed ID: 16637072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncogenic mechanisms of
    Cardoso M; Maia S; Paulo P; Teixeira MR
    Oncoscience; 2016; 3(9-10):288-296. PubMed ID: 28050579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 mutations and prostate cancer in Poland.
    Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J
    Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.
    Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.
    Cooney KA
    Trans Am Clin Climatol Assoc; 2017; 128():14-23. PubMed ID: 28790484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Darst BF; Sheng X; Eeles RA; Kote-Jarai Z; Conti DV; Haiman CA
    Eur Urol; 2021 Aug; 80(2):134-138. PubMed ID: 33941403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.
    Weiner AB; Faisal FA; Davicioni E; Karnes RJ; Griend DJV; Lotan TL; Schaeffer EM
    Eur Urol Oncol; 2021 Dec; 4(6):955-962. PubMed ID: 32540218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer.
    Lindmark F; Jonsson BA; Bergh A; Stattin P; Zheng SL; Meyers DA; Xu J; Grönberg H
    Prostate; 2004 May; 59(2):132-40. PubMed ID: 15042613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer.
    Akbari MR; Anderson LN; Buchanan DD; Clendenning M; Jenkins MA; Win AK; Hopper JL; Giles GG; Nam R; Narod S; Gallinger S; Cleary SP
    Cancer Epidemiol; 2013 Aug; 37(4):424-7. PubMed ID: 23541221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
    Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
    Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.